Adaptive Biotechnologies Corp

ADPT remains in a Stage 2 advancing regime powered by a parabola-driven acceleration. The stock is now pulling back into the rising 9 and 21 EMAs around the prior breakout zone, offering a structurally sound entry. Despite extreme overbought conditions, this retracement lacks exhaustion and aligns with the medium-term uptrend. Short-term execution conditions favor buying the pullback into EMAs to participate in continued trend acceleration.

• ↑45% YoY total revenue to $70.9M, led by 53% MRD sales surge.
• ↑Gross margin expanded to 70% (+8pp YoY); MRD segment delivered $12.1M adjusted EBITDA.
• ↓Net loss of $20M in Q1; negative earnings yield and high volatility risk.